ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Update

ADMA Biologics, Inc. (NASDAQ:ADMA) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 13,620,000 shares, a growth of 11.8% from the December 31st total of 12,180,000 shares. Based on an average daily trading volume, of 3,500,000 shares, the short-interest ratio is currently 3.9 days.

Analyst Upgrades and Downgrades

ADMA has been the subject of a number of research reports. HC Wainwright boosted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Raymond James upped their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $16.15 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm has a market capitalization of $3.82 billion, a price-to-earnings ratio of 57.68 and a beta of 0.76. The company’s 50-day moving average is $18.10 and its two-hundred day moving average is $17.61. ADMA Biologics has a 1-year low of $5.02 and a 1-year high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same period in the previous year, the business posted $0.01 EPS. Analysts forecast that ADMA Biologics will post 0.51 EPS for the current year.

Insider Buying and Selling at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of the business’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now owns 199,433 shares of the company’s stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ADMA Biologics

A number of hedge funds have recently added to or reduced their stakes in ADMA. Marshall Wace LLP lifted its holdings in ADMA Biologics by 44.1% during the 2nd quarter. Marshall Wace LLP now owns 26,800 shares of the biotechnology company’s stock worth $300,000 after buying an additional 8,203 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in ADMA Biologics by 17.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 129,739 shares of the biotechnology company’s stock worth $1,450,000 after buying an additional 18,977 shares in the last quarter. Algert Global LLC increased its position in shares of ADMA Biologics by 831.6% in the 2nd quarter. Algert Global LLC now owns 118,290 shares of the biotechnology company’s stock valued at $1,322,000 after purchasing an additional 105,593 shares during the last quarter. Creative Planning increased its position in shares of ADMA Biologics by 73.9% in the 2nd quarter. Creative Planning now owns 36,147 shares of the biotechnology company’s stock valued at $404,000 after purchasing an additional 15,363 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in shares of ADMA Biologics in the 2nd quarter valued at approximately $1,157,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.